Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
Axsome Therapeutics dosed the first patient in the FOCUS-2 Phase 3 trial evaluating solriamfetol for children aged 6 to less than 12 years with ADHD. The randomized, double-blind, placebo-controlled study will enroll approximately 468 patients to assess the drug's efficacy and safety over a 6-week treatment period, with the primary endpoint measuring change in the ADHD Rating Scale total score.
Key figures
- Drug Name
- Solriamfetol
- Phase Of Trial
- Phase 3
- Patient count
- 468
- Age range years
- 6 to less than 12
- Trial duration weeks
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.